Investor Presentation H1 2023

100 Investor presentation First six months of 2023 ZEUS trial with ziltivekimab aims to validate the link between inflammation and major adverse cardiovascular events R 1:1 Phase 3 CVOT trial ZEUS with ziltivekimab Investigate CV benefit in 6,200 patients ziltivekimab 15 mg sc once-monthly + SoC Placebo sc once-monthly + SoC Treatment period (event driven) 3 months follow-up Novo NordiskⓇ Objective • • To investigate the cardiovascular benefit of ziltivekimab in the treatment of patients with established ASCVD, CKD and systemic inflammation Primary endpoints Time to the first occurrence of 3-point MACE (CV death, non- fatal MI or non-fatal stroke) Secondary confirmatory endpoints Time to first occurrence of expanded MACE¹ • Number of hospitalisations for HF or urgent HF visit • Time to occurrence of all-cause mortality . Time to first occurrence of a composite CKD endpoint 1 MACE includes CV death, non-fatal MI or non-fatal stroke, Expanded MACE includes: (CV death, non-fatal MI, non-fatal stroke or hospitalisation for unstable angina pectoris requiring urgent coronary revascularisation) hsCRP: High-sensitivity C-reactive protein; CVOT: Cardiovascular outcome trial; CV: Cardiovascular; sc: Subcutaneous; SoC: Standard of care; HF: Heart failure; CKD: Chronic kidney disease Source: Ridker PM, et al., IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial, 17 May 2021

View entire presentation